Ashwagandha Side Effects: The Tolerance Threshold and What 29+ Clinical Trials Reveal
The Tolerance Threshold: What Real Clinical Trial Safety Data Reveals
Most ashwagandha side effects articles are written by affiliates with a financial interest in reassuring you. We take a different approach. Honest safety information builds the trust that matters long-term — and the evidence on ashwagandha's safety profile is genuinely reassuring when you understand The Tolerance Threshold.
The Tolerance Threshold is the dose below which ashwagandha is extremely well-tolerated, and above which certain side effects become more likely. Based on 29+ randomised controlled trials, that threshold sits at approximately 600mg per day of standardised root extract for most healthy adults. Below it: minimal adverse events across thousands of participants. Above it: not dangerous, but gastrointestinal complaints increase in a dose-dependent pattern.
Here is what the preliminary research actually shows — including the findings that should give you pause.
Common Side Effects: What 29+ RCTs Document
A 2024 systematic review and meta-analysis evaluating ashwagandha for anxiety and insomnia (PMID: 39083548) found no serious adverse events across included studies. A comprehensive safety review of 30 clinical trials covering over 2,500 participants (PMID: 32201301) documented the following mild, transient side effects:
- Gastrointestinal discomfort (nausea, loose stools, epigastric pain) — reported in 5–10% of participants in some trials. This is the most common side effect category.
- Drowsiness and somnolence — particularly with evening dosing. This may actually be beneficial for those using ashwagandha for sleep support.
- Headache — typically in the first week only, resolving without intervention.
- Less common effects — giddiness, nasal congestion, decreased appetite, dry mouth, and skin rash were reported at rates below 5%.
A dedicated safety RCT (PMID: 33338583, n=80, 8 weeks) specifically assessed safety in healthy volunteers receiving 600mg daily. The study found no clinically significant changes in liver function, kidney function, haematological parameters, or vital signs. No adverse events were reported by any participant — a notably clean safety signal.
The 2026 three-arm RCT (PMID: 41824889, n=135) and a 24-week weight management trial (PMID: 41635453, n=100) both reported only mild adverse events (nausea, abdominal pain, drowsiness) resolving without intervention — reinforcing the safety profile at doses used in studies of 300–600mg daily.
The Liver Concern: What Case Reports Mean (and What They Do Not Mean)
This is where honesty matters most. There have been documented case reports of drug-induced liver injury (DILI) associated with ashwagandha use, and they deserve serious discussion rather than dismissal.
A 2023 case report (PMID: 36900932) described a patient who developed jaundice after taking ashwagandha for one year. A 2023 review using the updated RUCAM causality assessment (PMID: 37631044) identified two new cases — a 36-year-old man after 6 months of 1,350mg daily, and a 30-year-old woman after 45 days of 450mg — both scoring "probable" causal relationship. A 2021 UK case (PMID: 34882134) documented hepatocellular injury with confluent necrosis in a 39-year-old woman. One reported case internationally resulted in liver transplantation.
Critical context: These are case reports — the lowest tier of evidence. The patients were often taking multiple supplements simultaneously. The doses in some cases exceeded what clinical trials have studied. Against these few cases, 29+ controlled trials with over 2,500 participants did not demonstrate liver toxicity at standard doses (PMID: 33338583). However, the case reports cannot be dismissed — they represent a real signal for susceptible individuals.
What remains unknown: whether specific formulations (leaf vs root, withaferin A content, extraction methods) carry differential liver risk. Whether certain genetic variants increase individual susceptibility. The case reports raise questions that controlled trials have not yet answered.
“29+ RCTs found no serious adverse events at standard doses. But case reports of liver injury — including one requiring transplantation — mean that long-term monitoring is reasonable, not optional.”
Thyroid Effects: A Double-Edged Property
Ashwagandha has a documented effect on thyroid function. A double-blind RCT in subclinical hypothyroid patients (PMID: 28829155, n=50, 8 weeks) found that 600mg daily significantly improved TSH, T3, and T4 levels compared to placebo (p < 0.001 for TSH). A secondary analysis from a bipolar disorder trial (PMID: 25624699) observed T4 increases of 7–24% in ashwagandha-treated patients.
This thyroid-stimulating effect is beneficial for subclinical hypothyroidism — but potentially problematic for people with hyperthyroidism, Graves' disease, or those on thyroid medication where precise dosing matters. The 2025 meta-analysis on stress and cortisol (PMID: 40746175, n=488) found significant cortisol reduction but showed no significant effect on perceived stress — a reminder that ashwagandha's hormonal effects do not always translate to subjective outcomes.
Who Should NOT Take Ashwagandha
This is the section most supplement companies prefer to bury. These are the populations for whom ashwagandha is contraindicated or requires direct medical supervision:
Pregnant women: Ashwagandha has been used traditionally as a uterine stimulant. High doses in animal models produced adverse pregnancy outcomes. There are no adequate human safety studies in pregnancy. Most studies on the mechanism were animal or in vitro. Avoid if pregnant or trying to conceive, unless under direct medical supervision.
People with thyroid conditions or on thyroid medication: The thyroid-stimulating effect (PMID: 28829155) means ashwagandha may interfere with levothyroxine or similar medication dosing. If you have Graves' disease or hyperthyroidism, ashwagandha is not recommended without endocrinologist oversight.
People with autoimmune conditions: Ashwagandha has immune-modulating properties. In people with lupus, rheumatoid arthritis, Hashimoto's thyroiditis, or MS, immune stimulation could theoretically exacerbate the autoimmune response. This caution is theoretical rather than clinical, but it is not suitable for dismissal given the mechanism of action.
People taking sedative or CNS-depressant medications: A systematic review of GABA-modulating phytomedicines (PMID: 29168225) confirmed ashwagandha's GABAergic activity. Combined with benzodiazepines, barbiturates, or sleep medications, additive sedation is possible. Consult your prescribing doctor before combining.
People with pre-existing liver conditions: Given the case reports (PMIDs: 36900932, 37631044), those with hepatitis, cirrhosis, or taking hepatotoxic medications should avoid ashwagandha or use only under medical supervision with liver function monitoring.
Pre-surgery patients: Ashwagandha may potentiate anaesthesia. Discontinue at least 2 weeks before any scheduled surgery.
The Honest Limitation on Long-Term Safety
Most ashwagandha RCTs run for 8–12 weeks. The dedicated 8-week safety study (PMID: 33338583) is reassuring but limited in duration. A 24-week trial (PMID: 41635453) provides the longest controlled safety data available, with no concerning signals — but that is still less than 6 months.
The 2025 meta-analysis (PMID: 40746175, n=488) found that ashwagandha produced significant cortisol reduction but showed no significant effect on perceived stress — a null finding that is important context when weighing the decision to supplement long-term. Biochemical changes do not guarantee subjective benefit.
Traditional Ayurvedic use over centuries provides some reassurance, but traditional patterns were typically cyclical — not year-round daily supplementation at concentrated extract doses. For healthy adults, 8–12 week cycles with a 2–4 week break stays within the well-studied safety window.
Side Effect Risk by Formulation Type
| Formulation | Typical Dose | GI Risk | Clinical Notes |
|---|---|---|---|
| Root extract, standardised | 300–600mg | Low | Best-studied; minimal adverse events at doses used in studies. Take with food. |
| Whole root powder | 1–3g | Low to moderate | Less concentrated; larger serving needed. Lower withanolide content per gram. |
| Leaf extract (high withaferin A) | Varies | Higher | Leaf material associated with more adverse effects and higher cytotoxicity in vitro. Avoid if possible. |
| High-dose (>600mg extract) | >600mg | Moderate | No additional benefit demonstrated in RCTs above 600mg. Dose-dependent GI increase. |
What This Means in Practice
For most healthy adults: You can take ashwagandha root extract at 300–600mg daily with good confidence. The safety data across 29+ RCTs and over 2,500 participants is genuinely strong. Start with 300mg daily for the first 2 weeks, then consider increasing to 600mg if tolerated. Take it with food to minimise GI risk.
If you experience GI side effects: Start with half your current dose for 2 weeks. Take it with your largest meal. If symptoms persist beyond 2 weeks at the reduced dose, discontinue and consult your healthcare professional.
If you experience drowsiness: Shift your dose to the evening. Combine with good sleep hygiene practices — the drowsiness may be a feature rather than a bug if sleep quality is your goal.
If you notice jaundice, dark urine, or unusual fatigue: These may be signs of liver stress. Discontinue immediately and see a healthcare professional. This is unlikely to help most people — the risk is very low — but the monitoring awareness is not optional.
When not to use ashwagandha: During pregnancy, with hyperthyroidism or Graves' disease, alongside sedative medications without medical guidance, or if you have active liver disease. If you are taking immunosuppressive medication for an autoimmune condition, ashwagandha is not appropriate without specialist approval.
Cycling protocol: Consider 8–12 weeks on, 2–4 weeks off. This stays within the strongest evidence window and aligns with traditional cyclical use patterns. Pair with regular health check-ups if using ashwagandha alongside other supplements or medications.
From Our Formulations
Our ashwagandha is root-only — no leaf material. This distinction matters for safety. The leaf contains higher concentrations of withaferin A, which shows greater cytotoxicity in vitro. Several of the liver injury case reports involved products of unknown or mixed plant-part composition.
We use a dual-extract process (hot water plus ethanol) at a 10:1 concentration ratio, yielding a minimum 2.5% withanolides while maintaining a full-spectrum profile. This is verified by certificate of analysis for every batch. Higher withanolide percentages are possible — but they typically require leaf material or aggressive extraction that strips the full-spectrum compounds. We maintain 2.5% specifically because it balances potency with the complete root profile that traditional use is based on.
Our ashwagandha is ACO-certified organic (Australian Certified Organic), sourced from Rajasthan, India, and third-party tested for heavy metals (lead, arsenic, cadmium, mercury) and microbial contaminants. E. coli: negative. Salmonella: negative. Every batch.
This matters in a side effects context because contamination — heavy metals, microbial contaminants, undeclared ingredients — is a real source of adverse reactions attributed to "ashwagandha" that may actually be caused by the product quality, not the herb itself.
Certified organic, root-only, dual-extracted ashwagandha
10:1 concentration. 2.5% withanolides. Third-party tested every batch. From 50g to 1kg.
Frequently Asked Questions
For dosing guidance, see our ashwagandha dosage guide. For specific health goals, explore ashwagandha for anxiety, ashwagandha for sleep, or ashwagandha and thyroid health.
Root-only. Dual-extracted. Third-party tested.
Certified organic ashwagandha sourced from Rajasthan. 10:1 concentration, 2.5% withanolides. Available from 50g ($40) to 1kg ($440).
Shop Ashwagandha →
Teelixir Organic Ashwagandha Root (10:1)
Dual-extracted • Root only • ACO Certified Organic • ≥2.5% withanolides
$40.00 AUD
Shop Ashwagandha →Continue Your Research
- Ashwagandha Benefits: The Complete Evidence-Based Guide
- Ashwagandha for Muscle Strength: The Anabolic Recovery Window Explained
- Ashwagandha for Women: Hormones, Perimenopause, and the Hormonal Seesaw
- Ashwagandha for Gut Health: The Stress-Gut Axis Short-Circuit
- Ashwagandha vs Lion's Mane: The Body-Brain Divide
- Ashwagandha and Magnesium: Close the Dual Calm Gap
- Ashwagandha Research: What 1,584 Studies Tell Us